In a six-day ATP-based endometrial cancer screen, the PAC-1 response-curve AUC was higher in REME9 and REME16 tumor organoids than in AN3 CA and RL95-2 cells, indicating lower sensitivity in those organoid models. The paper lists AdooQ BioScience as the PAC-1 supplier. Exact PAC-1 IC50 values were not extracted from this graphical screen. [2]
PAC-1–zinc binding in solution
Biochemical assay · PAC-1 and ZnSO4 in HEPES/KNO3 buffer [1]
Spectrophotometric continuous-variation analysis supported 1:1 zinc binding with a reported Kd of 42 nM. The paper also reports 55 nM by EGTA competition; these are metal-binding constants, not cellular potency.
Literature-Reported Treatment Conditions
- Treatment concentration
- PAC-1 + ZnSO4 total concentration 50 μM in continuous variations; PAC-1 50 μM for spectral titration.
- Method
- UV-visible absorbance; normalized absorbance at 410 nm; independent EGTA competition.
- Vehicle
- DMSO stocks diluted into aqueous buffer.
- Reported limits
- Figure 9a caption states pH 7.2, whereas Methods buffer A states pH 7.4; exact assay pH remains discrepant. A single pH is not assigned here.
Methods and source locations
Compound reported in the paper: PAC-1; Compound label in the paper: PAC-1
Applies to the PAC-1 material tested in this paper; no salt conversion or current supplier-lot validation.
Figure 9 and Results PAC-1 binds tightly to Zn2+; Methods Zinc Titration, Continuous Variations Method and EGTA Competition Titration
PAC-1–Zn2+ affinity: Continuous variations; 1:1 stoichiometry; Figure 9 error bars denote standard deviation. — Figure 9b; Results PAC-1 binds tightly to Zn2+
Independent metal-binding affinity estimate: EGTA competition, absorbance at 410 nm; main-text reported result, not a curve-derived estimate. — Results PAC-1 binds tightly to Zn2+, final paragraph; Methods EGTA Competition Titration
Buffer and zinc dependence of PAC-1 enzyme activity
Biochemical assay · Purified caspase-3 and procaspase-3 peptide-substrate assays [1]
PAC-1 increased enzyme activity under zinc-inhibited conditions. Removing inhibitory metals eliminated the activating effect; high PAC-1 concentrations inhibited activity. These results do not establish a universal cellular mechanism.
Literature-Reported Treatment Conditions
- Treatment concentration
- Figure 1: 50 μM PAC-1; Figure 4: 0.025–100 μM PAC-1, with or without 5 μM ZnSO4 (panels a–b).
- Exposure duration
- 2 h at 37°C before substrate addition; absorbance monitored for 1 h.
- Method
- Ac-DEVD-pNA hydrolysis at 405 nm; buffer and no-zinc controls.
- Vehicle
- DMSO matched across wells; activity method specifies never above 5%.
- Reported limits
- No exact activation EC50 adopted. Figure 4c has a zinc-dose discrepancy between caption and plotted label and is not used for a dose-specific claim.
Methods and source locations
Compound reported in the paper: PAC-1; Compound label in the paper: PAC-1
Applies to the PAC-1 material tested in this paper; no salt conversion or current supplier-lot validation.
Figures 1c–d and 4a–b; Results buffer dependence, metal removal and dose response; Methods Buffer Analysis and Assay of Procaspase-3/-7 and Caspase-3/-7 Activity
Effect of PAC-1 after buffer metal removal: 500 nM procaspase-3; 50 μM PAC-1 versus vehicle; Ac-DEVD-pNA 200 μM. — Figure 1d; Results Metal removal abolishes the activating effect of PAC-1; Methods Buffer Analysis
Enzyme activity with zinc versus zinc-free reference: Dose response; Figures 4a–b show 500 nM caspase-3/procaspase-3 with 5 μM ZnSO4. Representative of three trials; methods describe triplicate points and at least three repeats. — Figure 4a–b and caption; Results dose response; Discussion final paragraph
Orthogonal validation of zinc-dependent procaspase processing
Biochemical assay · Uncleavable procaspase-3(D9A/D28A/D175A) enzyme and catalytically inactive procaspase-3(C163A) substrate [1]
Zinc inhibited production of p17/p12 fragments; PAC-1 restored processing, whereas PAC-1a did not. Separating enzyme and substrate roles supports the biochemical zymogen mechanism without claiming cell-level specificity.
Literature-Reported Treatment Conditions
- Treatment concentration
- PAC-1 50 μM; ZnSO4 100 μM; D3A enzyme 10 μM; C163A substrate 50 μM.
- Exposure duration
- 0, 6 and 12 h at 37°C.
- Method
- Western blot detection of p17/p12 processing products.
- Vehicle
- DMSO compound stock; no-zinc and zinc-only controls.
- Co-treatment
- PAC-1 plus ZnSO4; parallel PAC-1a negative control.
- Reported limits
- Qualitative blot outcome; no densitometric percentage or catalytic constant adopted.
Methods and source locations
Compound reported in the paper: PAC-1; Compound label in the paper: PAC-1
Applies to the PAC-1 material tested in this paper; no salt conversion or current supplier-lot validation.
Figure 6; Results PAC-1 induces procaspase-3 automaturation; Methods Western blot analysis of procaspase-3 activation
Zinc-inhibited cleavage of procaspase substrate: Figure 6 lanes 1–3 no zinc, 4–6 zinc, 7–9 zinc + PAC-1, 10–12 zinc + PAC-1a. Methods report four repeats on two protein batches. — Figure 6 and caption; Methods Western blot analysis of procaspase-3 activation
PAC-1 in an endometrial organoid drug screen
Cell-based study · REME9 and REME16 patient-derived endometrial tumor organoids, compared with AN3 CA and RL95-2 cell lines [2]
The PAC-1 bars in the multi-agent screen showed higher growth-response AUC in the organoids than in either conventional cell line, consistent with lower sensitivity in the organoid models. No exact PAC-1 AUC or IC50 was transcribed from the graph.
Literature-Reported Treatment Conditions
- Exposure duration
- 144 h (6 days) after treatment.
- Method
- 384-well ATP-based CellTiter-Glo 3D viability assay; AUC calculated from growth-inhibition curves.
- Vehicle
- DMSO control; methods specify a maximum of 0.1%.
- Reported limits
- Concentration range is inconsistent: 384-well Methods state 1.0 nM–20 μM (ten dilutions), while Figure 6 caption states 0.1–20 μM. Exact exposure grid is unresolved. Figure reports means of triplicate experiments without exact PAC-1 numerical labels.
Methods and source locations
Compound reported in the paper: PAC-1; Compound label in the paper: PAC-1
Applies to the PAC-1 material tested in this paper; no salt conversion or current supplier-lot validation.
Table II PAC-1 row; Figure 6; Methods Compounds, Cell culture and Growth inhibition assays using multi-well plates; Results Evaluation of anticancer agents using F-PDOs
Growth inhibition response integrated over tested concentrations: Viewed Figure 6; higher response-curve AUC indicates lower growth inhibition. Figure caption: mean of triplicate experiments. — Figure 6 PAC-1 row and caption; Results Evaluation of anticancer agents using F-PDOs